BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar

Firm Aims To File Biosimilar Ustekinumab Candidate In Developed Markets In 2026

 
• By Chloe Kent
  
Hand pushing wooden block signifying phase 1, positioned above blocks signifying phase 2 and 3
Analysts estimate that BioFactura's ustekinumab represents a $50m market opportunity • Source: Shutterstock

More from Biosimilars

More from Products